Literature DB >> 21296322

Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.

Henry J Michtalik1, Hsin-Chieh Yeh, Catherine Y Campbell, Nowreen Haq, Haeseong Park, William Clarke, Daniel J Brotman.   

Abstract

The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a predictor of adverse events in patients with heart failure. We examined the relation between acute changes in NT-proBNP during a single hospitalization and subsequent mortality and readmission. The data from a cohort of 241 consecutive patients aged ≥ 25 years who had been admitted to an urban tertiary care hospital with a primary diagnosis of heart failure were analyzed. Creatinine and NT-proBNP were measured at admission and at discharge of the first admission. The patient demographics, co-morbidities, and length of stay were collected. The patients were prospectively grouped into 2 categories according to the acute changes in NT-proBNP: a decrease of ≥ 50% or <50% from admission to discharge. The primary composite outcome was readmission or death within 1 year of the first hospital admission. The unadjusted hazard ratio of readmission/death was 1.40 (95% confidence interval 0.97 to 2.01; p = 0.07) for those with a < 50% decrease in NT-proBNP compared to their counterparts with a ≥ 50% decrease. After adjustment for age, gender, race, and admission creatinine and NT-proBNP, the risk of readmission/death was 57% greater for those with a < 50% decrease (hazard ratio 1.57, 95% confidence interval 1.08 to 2.28; p = 0.02). An adjustment for co-morbidity, length of stay, and left ventricular ejection fraction did not significantly change this relation. Reductions in NT-proBNP of < 50% during an acute hospitalization for heart failure might be associated with an increased hazard of readmission/death, independent of age, gender, race, creatinine, admission NT-proBNP, co-morbidities, left ventricular ejection fraction, and length of stay. In conclusion, patients with a < 50% reduction in NT-proBNP might benefit from more intensive medical treatment, monitoring, and follow-up.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296322     DOI: 10.1016/j.amjcard.2010.12.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  De novo acute heart failure and acutely decompensated chronic heart failure.

Authors:  Astrid Hummel; Klausn Empe; Marcus Dörr; Stephan B Felix
Journal:  Dtsch Arztebl Int       Date:  2015-04-24       Impact factor: 5.594

Review 2.  Biomarkers in heart failure: the past, current and future.

Authors:  Michael Sarhene; Yili Wang; Jing Wei; Yuting Huang; Min Li; Lan Li; Enoch Acheampong; Zhou Zhengcan; Qin Xiaoyan; Xu Yunsheng; Mao Jingyuan; Gao Xiumei; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 3.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

4.  Serial Measurement of Amino-Terminal Pro-B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Outcome in Children With Primary Myocardial Dysfunction and Acute Decompensated Heart Failure.

Authors:  Shivanand Shankar Medar; Daphne T Hsu; H Michael Ushay; Jacqueline M Lamour; Hillel W Cohen; James S Killinger
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

5.  Use of novel and conventional biomarkers for management of patients with heart failure.

Authors:  Kelly H Schlendorf; Edward K Kasper
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

6.  Prognostic significance of a multimarker strategy of biomarkers in acute heart failure.

Authors:  P Srinivas; C N Manjunath; Shaheena Banu; K S Ravindranath
Journal:  J Clin Diagn Res       Date:  2014-09-20

7.  Clinical Research on Brain Natriuretic Peptide Guiding the Application of β1 Receptor Blocker in Patients with Moderate to Severe Heart Failure.

Authors:  Jiang-Jin Li; Xiao-Li Xiang; Xiao-Yi Tian; Ya-Fei Shi
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

8.  Predictors of 30-day readmission in patients hospitalized with decompensated heart failure.

Authors:  Marlow B Hernandez; Randall S Schwartz; Craig R Asher; Elsy V Navas; Victor Totfalusi; Ivan Buitrago; Ankush Lahoti; Gian M Novaro
Journal:  Clin Cardiol       Date:  2013-08-08       Impact factor: 2.882

9.  Recommendations for Preoperative Assessment and Shared Decision-Making in Cardiac Surgery.

Authors:  Maks Mihalj; Thierry Carrel; Richard D Urman; Frank Stueber; Markus M Luedi
Journal:  Curr Anesthesiol Rep       Date:  2020-03-04

10.  Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography.

Authors:  Maria-José Ferrandis; Ingvar Ryden; Tomas L Lindahl; Anders Larsson
Journal:  Ups J Med Sci       Date:  2012-12-12       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.